© 2024 WEMU
Serving Ypsilanti, Ann Arbor and Washtenaw County, MI
Play Live Radio
Next Up:
0:00 0:00
Available On Air Stations

Michigan House panel adopts COVID 'right-to-try' bill

AstraZeneca COVID-19 Vaccine

Michigan already has a “right-to-try” law that allows people facing serious illnesses to turn to experimental remedies with a doctor’s approval. But this bill is different in that it specifically names COVID as a covered illness as long as the treatment has cleared the initial stage of the FDA approval process, says Republican Representative Mary Whiteford.

“So it’s very clear: It’s got to be safe to start with. It just hasn’t advanced in clinical studies to address COVID specifically,” said Whiteford.

But the bill is opposed by some Democrats, who argue that’s beside the point.

Democratic Representative Laurie Pohutsky said the bill can still be used to provide cover for those who want to prescribe or take questionable treatments such as Ivermectin, which is approved to treat parasitic infections, or hydroxychloroquine, which is an approved anti-malaria drug. But neither is approved to treat COVID.

“So a drug can be FDA-approved for something but still not be suitable to treat something else,” said Pohutsky.

She also said the bill appears to be an effort to rationalize the use of a controversial treatments.

“The right-to-try act doesn’t preclude any particular diseases,” she said, “so there’s no reason to specifically name one other than to purposefully feed into a narrative about that illness.”

The bill now goes to the House floor.

House Bill 5637 as introduced can be found here.

House Fiscal Agency bill analysis of House Bill 5637 can be found here.

Non-commercial, fact based reporting is made possible by your financial support.  Make your donation to WEMU todayto keep your community NPR station thriving.

Like 89.1 WEMU on Facebook and follow us on Twitter

Contact WEMU News at734.487.3363 or email us at studio@wemu.org

Rick Pluta is the managing editor for the Michigan Public Radio Network.
Related Content